Last reviewed · How we verify
XP21279
At a glance
| Generic name | XP21279 |
|---|---|
| Also known as | XP21279 sustained related |
| Sponsor | XenoPort, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects (PHASE1, PHASE2)
- A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XP21279 CI brief — competitive landscape report
- XP21279 updates RSS · CI watch RSS
- XenoPort, Inc. portfolio CI